Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
An audio source and summary of the top stories from the field of addiction medicine.
Tuesday Oct 08, 2024
Tuesday Oct 08, 2024
Tuesday Oct 08, 2024
Cannabis Policy Impacts Public Health and Health Equity
National Academy of Sciences Engineering Medicine
This report from the National Academies of Sciences, Engineering, and Medicine urges the federal government to provide policy guidance to states that have legalized cannabis, close regulatory loopholes on intoxicating products derived from hemp, and create a public health campaign aimed at parents and vulnerable populations, among other measures that would protect public health and reduce the harms of rising cannabis use. Federal action includes closing regulatory loopholes for hemp-derived cannabinoids, a cannabis public health campaign, best practices for cannabis policy, and improved cannabis public health data and allowing research. State action includes required training for cannabis retail staff, automatically expunging criminal records, a model for state cannabis policy, and setting product standards.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Monday Sep 30, 2024
Monday Sep 30, 2024
In this episode recorded live at ASAM's 55th Annual Conference in Fort Worth, TX, host Dr. Nick Athanasiou sat down with Dr. Shannon Miller to discuss his work on PAM-7, and his path to addiction medicine.
Subscribe to the ASAM Weekly
Tuesday Sep 24, 2024
Tuesday Sep 24, 2024
Tuesday Sep 24, 2024
Risk of Incident Psychosis and Mania With Prescription Amphetamines
The American Journal of Psychiatry
This case-control study used electronic health records to examine the impact of dose levels of prescription amphetamines on the risk of incident psychosis and mania with prescription amphetamines. Among 1,374 case subjects and 2,748 control subjects, the odds of psychosis and mania were increased for individuals with past-month prescription amphetamine use compared with no use. A dose-response relationship was observed; high doses of amphetamines (>30 mg dextroamphetamine equivalents) were associated with 5.28-fold increased odds of psychosis or mania. Past-month methylphenidate use was not associated with increased odds of psychosis or mania compared with no use. Caution should be exercised when prescribing high doses of amphetamines, with regular screening for symptoms of psychosis or mania.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Sep 17, 2024
Tuesday Sep 17, 2024
Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders 🔓
JAMA Network Open
This cross-sectional study of 9,438,716 commercially insured patients examined if access to cannabis, via medical or recreational legalization, is associated with changes in the dispensing of prescription medications to treat mental health disorders. Researchers found statistically significant reductions in benzodiazepine dispensing after increases in both medical and recreational cannabis access. However, evidence suggests increases in other types of psychotropic dispensing. The study suggests that cannabis laws may be significantly associated with the population-level use of prescription drugs to treat mental health disorders, although the associations vary by drug class and state.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Sep 10, 2024
Tuesday Sep 10, 2024
State-level racial and ethnic disparities in buprenorphine treatment duration in the United States
The American Journal on Addictions
National trends reveal a concerning escalation in racial and ethnic disparities in buprenorphine treatment duration for opioid use disorder. This study examined such disparities at the state level. Analyzing 9,040,620 buprenorphine prescriptions dispensed between January 2011 and December 2020 from IQVIA Longitudinal Prescription data, the study revealed substantial statewide variations in racial and ethnic disparities. Specifically, 21 states showed longer treatment durations for White people across all episodes, and 8 states displayed similar trends among episodes lasting ≥180 days. Longer treatment durations for White people in both overall and long-term episodes were exhibited in 5 states, and 15 states showed no racial and ethnic disparities.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Wednesday Sep 04, 2024
Wednesday Sep 04, 2024
Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial 🔓
Annals of Medicine
Mindfulness-Oriented Recovery Enhancement (MORE) uses mindfulness training to address dysregulation in brain reward systems. MORE has been shown to reduce drug cue reactivity and in an RCT reduced opioid misuse 45% at 9 months. Face-to-face MORE requires significant time of trained clinicians, and this study explored the feasibility of delivering MORE by virtual reality (VR). Treatment consisted of 8 weekly, one-hour MORE-VR sessions. Patients could choose the VR setting for their meditation (beach, forest, waterfall) and interact with virtual drugs and paraphernalia during session 5, which was devoted to examining and managing craving. Of 38 patients, 68% completed 4 or more sessions and 50% completed all sessions. Opioid use decreased significantly (p =.04), as well as craving (p<.001), and results showed a significant increase in positive affect (p<.001).
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 27, 2024
Tuesday Aug 27, 2024
Tuesday Aug 27, 2024
The Lancet Psychiatry Commission on youth mental health🔓
The Lancet Psychiatry
Mental ill health, which has been the leading health and social issue impacting the lives and futures of young people for decades, has entered a dangerous phase. Accumulating research evidence indicates that in many countries, the mental health of emerging adults has been declining steadily over the past two decades, with a major surge of mental ill health driven by the COVID-19 pandemic, the measures taken to contain it, and its aftermath. This alarming trend signals a warning that global megatrends (major, long-lasting societal changes such as environmental, social, economic, political, or technological changes) and changes in many societies around the world in the past two decades have harmed the mental health of young people and increased mental ill health among them.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 20, 2024
Tuesday Aug 20, 2024
Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors
JAMA Network Open
This British study included 135,103 older (median age 64) adults and compared drinking patterns with mortality during a median follow-up of 12 years. Compared to occasional drinkers, low-risk drinkers had higher cancer mortality (HR, 1.11), moderate-risk drinkers had higher all-cause and cancer mortality (HRs, 1.10 and 1.15), and high-risk drinking had higher all-cause, cancer, and cardiovascular mortality (HRs, 1.33, 1.39, and 1.21). These results contrast with earlier studies showing protective effects of low- to moderate-risk drinking. Researchers used occasional drinkers as the control group, where previous studies used abstainers including former drinkers with residual health effects. There was a small protective effect of drinking only with meals and drinking wine. In conclusion, the authors failed to find a protective effect of low-risk drinking on mortality.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 13, 2024
Tuesday Aug 13, 2024
Tuesday Aug 13, 2024
Physician Reluctance to Intervene in Addiction: A Systematic Review
JAMA Network Open
This systematic review of 283 articles explored the reasons physicians give for not addressing substance use and addiction in their clinical practice. The institutional environment (81.2% of articles) was the most common reason given for physicians not intervening in addiction, followed by lack of skill (73.9%), cognitive capacity (73.5%), and knowledge (71.9%). These findings suggest that efforts should be directed at creating institutional environments that facilitate the delivery of evidence-based addiction care while improving access to education and training opportunities for physicians to practice the necessary skills.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 06, 2024
Tuesday Aug 06, 2024
Host Dr. Nick Athanasiou sat down with Drs. Matisyahu Shulman and Adam Bisaga to discuss the study they recently authored titled Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Trial. The doctors share their findings and the impact and implications of the study.
Subscribe to The ASAM Weekly to read the guest editorial:
Guest Editorial: Rapid Initiation of Injectable Extended-Release Naltrexone for Opioid Use Disorder: A Time for Paradigm Shift in Treatment Protocols
This project has been funded as a whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N95020C00028.
ASAM, founded in 1954, is a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine.
ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction.
Visit www.ASAM.org for more information.
Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
Disclaimer:
This podcast is for informational purposes only and should not be considered health advice.
• We are not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.
• This podcast is not intended to replace professional medical advice.
• The views expressed in this podcast may not be those of the host or the management.